PUBLISHER: The Business Research Company | PRODUCT CODE: 2057525
PUBLISHER: The Business Research Company | PRODUCT CODE: 2057525
Cancer tumor profiling refers to the comprehensive molecular and genetic analysis of cancerous tissues to identify specific mutations, gene expressions, protein markers, epigenetic modifications and other biological characteristics associated with a tumor. It is used to characterize the molecular architecture of cancer and to guide clinical and research decision-making in oncology.
The cancer tumor profiling market consists of sales by entities (organizations, sole traders and partnerships) of cancer tumor profiling that are used by oncologists, pathologists, molecular biologists, academic researchers, pharmaceutical and biotechnology companies and contract research organizations. It is applied at the time of initial diagnosis to classify tumor subtypes, during treatment selection to identify actionable targets, throughout therapy to monitor response or resistance and at recurrence to reassess tumor evolution.
The global cancer tumor profiling market was valued at $8,093.5 million in 2020 which grew till 2025 at a compound annual growth rate (CAGR) of more than 13.00%.
Rising Global Cancer Incidence
During the historic period, the cancer tumor profiling market was significantly driven by the rising global cancer incidence. Cancer is a disease characterized by the uncontrolled growth and spread of abnormal cells that can invade surrounding tissues and potentially spread to other parts of the body. One key factor contributing to the rising incidence of cancer is the aging population, as the likelihood of genetic mutations and cellular damage increases with age. With longer life expectancy worldwide, more individuals fall into high-risk age groups, leading to a greater number of cancer cases. Cancer tumor profiling supports cancer management by analyzing the molecular and genetic characteristics of tumors, enabling deeper understanding of tumor behavior and guiding more informed clinical decision-making. For example, in February 2024, according to the WHO (World Health Organization), a specialized agency of the United Nations which coordinates responses to international public health issues and emergencies, in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths. The estimated number of people who were alive within 5 years following a cancer diagnosis was 53.5 million. About 1 in 5 people develop cancer in their lifetime, approximately 1 in 9 men and 1 in 12 women die from the disease. , over 2 million new cancer cases are projected for the U.S. in 2024. Therefore, the cancer tumor profiling market was significantly driven by the rising global cancer incidence during the historic period.
Biotechnology, Genomics And Precision Medicine
Major companies in the cancer tumor profiling market are increasingly prioritizing biotechnology, genomics and precision medicine to enhance the accuracy, depth and clinical relevance of molecular diagnostics. By integrating advanced sequencing technologies, multi-omics platforms and AI-driven analytics, they aim to deliver comprehensive insights into tumor biology and actionable genetic alterations. Biotechnology, genomics and precision medicine play a critical role in advancing cancer tumor profiling by enabling detailed molecular characterization of tumors at the DNA, RNA and protein levels. Advanced sequencing technologies, such as next-generation sequencing and multi-omics platforms, allow for the identification of genetic mutations, biomarkers and pathway alterations that drive cancer progression. Precision medicine frameworks use these insights to guide targeted therapy selection, optimize treatment response and minimize unnecessary interventions. Biotechnology innovations further support the development of high-sensitivity assays, including liquid biopsy and companion diagnostics, enhancing early detection and disease monitoring. Collectively, these advancements are reshaping the cancer tumor profiling landscape by shifting it from conventional histopathological analysis toward data-driven, personalized oncology solutions that improve clinical decision-making and patient outcomes.
The global cancer tumor profiling market is fragmented, with a large number of small players operating in the market. The top 10 competitors in the market made up 14.070% of the total market in 2024.
Cancer Tumor Profiling Global Market Opportunities And Strategies To 2035 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global cancer tumor profiling market as it emerges from the COVID-19 shut down.
Where is the largest and fastest-growing market for cancer tumor profiling? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The cancer tumor profiling market global report from The Business Research Company answers all these questions and many more.
The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider cancer tumor profiling market; and compares it with other markets.